Como citar este artigo
Martins JVD, Mendes R, Lopes JM, Tenório PP. . Arq. Bras. Cardiol. 2022;119(5):813-4.
Martins, João Victor Domiciano; Mendes, Rodrigo; Lopes, Johnnatas Mikael; Tenório, Pedro Pereira. . Arq. Bras. Cardiol., v. 119, n. 5, p. 813-814, nov. 2022.
Martins, J. V. D., Mendes, R., Lopes, J. M., & Tenório, P. P. (2022). . Arq. Bras. Cardiol., 119(5), 813-814.
Martins, João Victor Domiciano and Mendes, Rodrigo and Lopes, Johnnatas Mikael and Tenório, Pedro Pereira. . Arq. Bras. Cardiol. [online]. 2022, vol. 119, n. 5, [cited 2025-09-09], pp.813-814. Available from: <https://abccardiol.org/article/11591/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.